Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

Схожие документы

• Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
  по: van der Maas, Aatke, et al.
  Опубликовано: (2012)
• The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis
  по: van den Bemt, Bart J F, et al.
  Опубликовано: (2013)
• DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis
  по: van Riel, Piet LCM, et al.
  Опубликовано: (2005)
• Time to achieve remission determines time to be in remission
  по: Schipper, Lydia G, et al.
  Опубликовано: (2010)
• Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
  по: den Broeder, Alfons A, et al.
  Опубликовано: (2013)